Skip to main content

Management of functional abdominal pain

Current Treatment Options in Gastroenterology volume 7, pages 279–290 (2004)Cite this article

Opinion statement

The diagnosis of functional abdominal pain should be made based on the Rome II symptom criteria with only limited testing to exclude other disease. During physical examination the clinician may look for evidence of pain behavior which would be supportive of the diagnosis. Reassurance and proper education regarding the clinical entity of functional abdominal pain is critical for successful treatment and good patient satisfaction. Education should include validation that symptoms are real, and that other individuals experience similar symptoms. No further treatment may be required for those with mild symptoms. For patients with more severe symptoms, a long-term management plan of either pharmacological or psychological treatments is warranted. This will require a commitment by both the patient and the physician to engage in a partnership with active involvement and responsibility by both individuals. The goal of treatment—to decrease pain and increase function over time, not to cure the disorder— should be explained. Strong consideration should be made for the use of an antidepressant to treat analgesic effects. Tricyclic antidepressants are the mainstay of therapy for functional pain disorders. The analgesic effect is generally quicker in onset and occurs at a lower dose than their effect on mood. To maximize patient compliance, patients should be told the rationale behind their use, warned of the potential side effects, and reassured that many of the side effects will disappear with time. Choice of an antidepressant should be based on the presence of concomitant symptoms (eg, depression), cost, and physician familiarity with specific agents. All patients with functional abdominal pain should be screened for underlying psychiatric disturbance as an untreated mood disorder will adversely affect response to treatment. If a concurrent mood disorder is found, it should be treated by either using a higher dose of the tricyclic antidepressant or by adding another antidepressant agent. Psychological interventions such as cognitive behavioral therapy may be important as adjuvant therapy or as an alternative to treatment with antidepressants for those patients who find antidepressants ineffective or are intolerant to them. Narcotics and benzodiazepines should not be used to treat chronic abdominal pain due to the high risk of physical and psychological dependence.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(suppl 2):II43–1147.

    PubMed  Article  Google Scholar 

  2. Drossman DA, Li Z, Andruzzi E, et al.: US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38: 1569–1580.

    PubMed  Article  CAS  Google Scholar 

  3. Bharucha AE, Camilleri M: Functional abdominal pain in the elderly. Gastroenterol Clin North Am 2001, 30: 517–529.

    PubMed  Article  CAS  Google Scholar 

  4. Eslick GD, Howell SC, Hammer J, Talley NJ: Empirically derived symptom subgroups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome: a factor and cluster analysis of a patient sample. Aliment Pharmacol Ther 2004, 19: 133–140.

    PubMed  Article  CAS  Google Scholar 

  5. Kwan AC, Bao TN, Chakkaphak S, et al.: Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol 2003, 18: 796–802.

    PubMed  Article  Google Scholar 

  6. Locke GR: The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996, 25: 1–19.

    PubMed  Article  Google Scholar 

  7. Triadafilopoulos G, Simms RW, Goldenberg DL: Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 1991, 36: 59–64.

    PubMed  Article  CAS  Google Scholar 

  8. Aaron LA, Buchwald D: A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001, 134: 868–881.

    PubMed  CAS  Google Scholar 

  9. Aaron LA, Burke MM, Buchwald D: Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000, 160: 221–227.

    PubMed  Article  CAS  Google Scholar 

  10. Sloth H, Jorgensen LS: Chronic non-organic upper abdominal pain: diagnostic safety and prognosis of gastrointestinal and non-intestinal symptoms. A 5-to 7-year follow-up study. Scand J Gastroenterol 1988, 23: 1275–1280.

    PubMed  CAS  Google Scholar 

  11. Budavari AI, Olden KW: Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Clin North Am 2003, 32: 477–506.

    PubMed  Article  Google Scholar 

  12. Drossman DA, Talley NJ, Leserman J, et al.: Sexual and physical abuse and gastrointestinal illness: review and recommendations. Ann Intern Med 1995, 123: 782–794.

    PubMed  CAS  Google Scholar 

  13. North CS, Alpers DH, Thompson SJ, Spitznagel EL: Gastrointestinal symptoms and psychiatric disorders in the general population: findings from NIMH Epidemiologic Catchment Area Project. Dig Dis Sci 1996, 41: 633–640.

    PubMed  Article  CAS  Google Scholar 

  14. Drossman DA: Chronic functional abdominal pain. Am J Gastroenterol 1996, 91: 2270–2281. A classic paper that provides a more in-depth background on chronic FAP and its treatment.

    PubMed  CAS  Google Scholar 

  15. Drossman DA, Fullwood A: Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995, 123: 688–697.

    PubMed  CAS  Google Scholar 

  16. Carter GT, Sullivan MD: Antidepressants in pain management. Curr Opin Investig Drugs 2002, 3: 454–458.

    PubMed  CAS  Google Scholar 

  17. Sawynok J, Esser MJ, Reid AR: Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci 2001, 26: 21–29.

    PubMed  CAS  Google Scholar 

  18. Prakash C, Clouse RE: Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999, 44: 2373–2379.

    PubMed  Article  CAS  Google Scholar 

  19. Rajagopalan M, Kurian G, John J: Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998, 13: 738–741.

    PubMed  CAS  Google Scholar 

  20. Creed F, Fernandes L, Guthrie E: et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124: 303–317.

    PubMed  Article  Google Scholar 

  21. Eisendrath SJ, Kodama KT: Fluoxetine management of chronic abdominal pain. Psychosomatics 1992, 33: 227–229.

    PubMed  CAS  Google Scholar 

  22. Godfrey RG: A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med 1996, 156: 1047–1052.

    PubMed  Article  CAS  Google Scholar 

  23. Barkin RL, Fawcett J: The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000, 7: 31–47.

    PubMed  CAS  Article  Google Scholar 

  24. Rudin NJ: Chronic pain rehabilitation: principles and practice. WMJ 2001, 100: 36–43, 66.

    PubMed  CAS  Google Scholar 

  25. Hasler WL, Schoenfeld P: Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17: 997–1005.

    PubMed  Article  CAS  Google Scholar 

  26. Kennedy TM, Jones RH: Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000, 87: 1658–1663.

    PubMed  Article  CAS  Google Scholar 

  27. Valim V, Oliveira L, Suda A: et al.: Aerobic fitness effects in fibromyalgia. J Rheumatol 2003, 30: 1060–1069.

    PubMed  Google Scholar 

  28. Culos-Reed SN, Brawley LR: Fibromyalgia, physical activity, and daily functioning: the importance of efficacy and health-related quality of life. Arthritis Care Res 2000, 13: 343–351.

    PubMed  Article  CAS  Google Scholar 

  29. Clouse RE: Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994, 39: 2352–2363.

    PubMed  Article  CAS  Google Scholar 

  30. Clouse RE, Lustman PJ: Antidepressants for IBS. In Irritable Bowel Syndrome: Diagnosis and Treatment. Edited by Camilleri M, Spiller R. London: W.B. Saunders; 2002: 161–171. An excellent overview on the use of antidepressants in patients suffering from functional gastrointestinal disorders with an emphasis on irritable bowel syndrome. This chapter provides practical advice on dosing and when it is necessary to check drug levels.

    Google Scholar 

  31. Fishbain D: Evidence-based data on pain relief with antidepressants. Ann Med 2000, 32: 305–316.

    PubMed  CAS  Google Scholar 

  32. Longstreth GF, Wilson A, Knight K, et al.: Irritable bowel syndrome, health care use, and costs: a US managed care perspective. Am J Gastroenterol 2003, 98: 600–607.

    PubMed  Article  Google Scholar 

  33. Talley NJ, Owen BK, Boyce P, Paterson K: Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996, 91: 277–283.

    PubMed  CAS  Google Scholar 

  34. Toner BB, et al.: Cognitive-Behavioral Treatment of Irritable Bowel Syndrome: The Brain-Gut Connection. Treatment Manuals for Practitioners. Edited by Barlow DH. New York: The Guilford Press; 2000. This book, written by psychologists who specialize in treating patients with functional gastrointestinal disorders, is an excellent reference explaining the rationale behind the cognitivebehavioral model and a practical guide to treatment for those who wish to administer CBT.

    Google Scholar 

  35. Drossman DA, et al.: AUTHOR: Please supply at least two more author names: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125: 19–31.

    PubMed  Article  Google Scholar 

  36. Hiller W, Fichter MM, Rief W: A controlled treatment study of somatoform disorders including analysis of health care utilization and cost-effectiveness. J Psychosom Res 2003, 54: 369–380.

    PubMed  Article  Google Scholar 

  37. Palsson OS, Turner MJ, Johnson DA, et al.: Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002, 47: 2605–2614.

    PubMed  Article  Google Scholar 

  38. Houghton LA, Calvert EL, Jackson NA, et al.: Visceral sensation and emotion: a study using hypnosis. Gut 2002, 51: 701–704.

    PubMed  Article  CAS  Google Scholar 

  39. Anbar RD: Self-hypnosis for the treatment of functional abdominal pain in childhood. Clin Pediatr 2001, 40: 447–451.

    CAS  Google Scholar 

  40. Keefer L, Blanchard EB: A 1-year follow-up of relaxation response meditation as a treatment for irritable bowel syndrome. Behav Res Ther 2002, 40: 541–546.

    PubMed  Article  CAS  Google Scholar 

  41. Drossman DA: Psychosocial sound bites: exercises in the patient-doctor relationship. Am J Gastroenterol 1997, 92: 1418–1423.

    PubMed  CAS  Google Scholar 

  42. Drossman DA: Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998, 60: 258–267.

    PubMed  CAS  Google Scholar 

  43. Sindrup SH, Bach FW, Madsen C, et al.: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003, 60: 1284–1289.

    PubMed  CAS  Google Scholar 

  44. Sayar K, Aksu G, Ak I, Tosun M: Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003, 37: 1561–1565.

    PubMed  Article  CAS  Google Scholar 

  45. Chial HJ, Camilleri M, Burton D, et al.: Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003, 284: G130-G107.

    PubMed  CAS  Google Scholar 

  46. Viramontes BE, et al.: Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001, 281: G1468-G1476.

    PubMed  CAS  Google Scholar 

  47. Pittler MH, Ernst E: Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastroenterol 1998, 93: 1131–1135.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Yuri A. Saito MD, MPH & Jean C. Fox MD

Authors
  1. Yuri A. Saito MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean C. Fox MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Saito, Y.A., Fox, J.C. Management of functional abdominal pain. Curr Treat Options Gastro 7, 279–290 (2004). https://doi.org/10.1007/s11938-004-0014-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-004-0014-4

Keywords

  • Irritable Bowel Syndrome
  • Fibromyalgia
  • Main Side Effect
  • Main Drug Interaction
  • Chronic Abdominal Pain